Related Experiment Videos
Albumin supplementation in the critically ill. A prospective, randomized trial
E F Foley1, B C Borlase, W H Dzik
1Department of Surgery, Harvard University Medical School, New England Deaconess Hospital, Boston, Mass.
Archives of Surgery (Chicago, Ill. : 1960)
|June 1, 1990
Summary
Albumin supplementation for critically ill patients with low albumin levels (hypoalbuminemia) showed no clinical benefit. This study found no improvement in mortality or complications, questioning the value of albumin therapy.
Area of Science:
- Critical Care Medicine
- Clinical Nutrition
- Biochemistry
Background:
- Hypoalbuminemia is common in critically ill patients.
- Albumin replacement therapy is controversial for this population.
- Evidence for clinical benefit remains inconclusive.
Purpose of the Study:
- To evaluate the efficacy of 25% albumin administration in hypoalbuminemic critically ill patients.
- To determine if albumin supplementation improves clinical outcomes.
- To assess the cost-effectiveness of albumin therapy.
Main Methods:
- Prospective, randomized trial involving 40 hypoalbuminemic critically ill patients.
- Treatment group received 25% albumin to maintain serum albumin ≥25 g/L.
- Control group received no concentrated albumin.
Main Results:
- No significant difference in mortality between treatment (39%) and control (27%) groups.
- No significant difference in major complication rates (89% vs 77%).
- No improvements in hospital stay, ICU stay, ventilator dependence, or enteral feeding tolerance.
Conclusions:
- Albumin replacement therapy did not demonstrate clinical benefit in this study population.
- The use of exogenous albumin for hypoalbuminemia in critically ill patients is not justified.
- Further research may be needed to identify specific subgroups that could benefit from albumin therapy.